Compass Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Compass Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2018 to Q2 2024.
  • Compass Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$13.1M, a 15.9% decline year-over-year.
  • Compass Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$47.2M, a 10.7% decline year-over-year.
  • Compass Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$42.5M, a 8.33% decline from 2022.
  • Compass Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$39.2M, a 52.3% increase from 2021.
  • Compass Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$82.2M, a 179% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$47.2M -$13.1M -$1.8M -15.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$45.4M -$10.8M -$2.95M -37.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-12
Q4 2023 -$42.5M -$13.4M -$1.82M -15.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$40.7M -$9.96M +$2.01M +16.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$42.7M -$11.3M -$2.78M -32.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$39.9M -$7.84M -$675K -9.43% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-12
Q4 2022 -$39.2M -$11.6M +$1.39M +10.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$40.6M -$12M -$6M -100% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$34.6M -$8.49M +$47.3M +84.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$81.9M -$7.16M +$260K +3.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$82.2M -$13M -$4.59M -54.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 -$77.6M -$5.98M +$3.18M +34.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$80.8M -$55.8M -$50.2M -904% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$30.5M -$7.42M -$1.02M -15.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$29.5M -$8.39M -$8.38M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-18
Q3 2020 -$21.1M -$9.15M -$598K -6.99% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$20.5M -$5.56M +$3.25M +36.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$23.8M -$6.4M +$4.37M +40.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 -$28.1M -$11.7K* +$10.1M Oct 1, 2019 Dec 31, 2019 10-Q 2020-02-14
Q3 2019 -$38.3M -$8.55M +$4K +0.05% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$38.3M -$8.81M -$335K -3.95% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-09
Q1 2019 -$37.9M -$10.8M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-09
Q4 2018 -$10.1M Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-14
Q3 2018 -$8.56M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 -$8.47M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.